Vitamin D3 treatment for locally advanced thyroid cancer: A case report

Endocrine Journal

Volumn 52, Issue 5, 2005, Pages 613-616

  Morishita, Mariko ^a,b   Ohtsuru, Akira ^b   Kumagai, Atsushi ^a   Namba, Hiroyuki ^a   Sato, Noriko ^b   Hayashi, Tomayoshi ^b   Yamashita, Shunichi ^a,b  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Advanced thyroid cancer; Dormancy; Thyroglobulin; Vitamin D3

Indexed keywords

ALPHAROL; COLECALCIFEROL; THYROGLOBULIN;

ADVANCED CANCER; AGED; ARTICLE; BLOOD VESSEL; CANCER LOCALIZATION; CANCER PATIENT; CANCER THERAPY; CASE REPORT; CELL PROLIFERATION; DISEASE SEVERITY; DRUG EFFICACY; ESOPHAGUS; FEMALE; HUMAN; IN VITRO STUDY; METASTASIS; QUALITY OF LIFE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID GLAND; TRACHEA; TUMOR GROWTH;

AGED; CARCINOMA, PAPILLARY; CHOLECALCIFEROL; FEMALE; HUMANS; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 27744496744     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.52.613     Document Type: Article

References (19)

1. Guyton KZ, Kensler TW, Posner GH (2003) Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 61: 227-238.
2. Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao XY, De Clercq P, Vandewalle M, Bouillon R (2000) Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 15: 2673-2679.
3. Oades GM, Dredge K, Kirby RS, Colston KW (2002) Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90: 607-616.
4. Evans SR, Shchepotin EI, Young H, Rochon J, Uskokovic M, Shchepotin IB (2000) 1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol 16: 1249-1254.
5. Okano K, Usa T, Ohtsuru A, Tsukazaki T, Miyazaki Y, Yonekura A, Namba H, Shindoh H, Yamashita S (1999) Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth. Endocr J 46: 243-252.
6. Liu W, Asa SL, Fantus IG, Walfish PG, Ezzat S (2002) Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol 160: 511-519.
7. Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL (2004) Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 145: 5840-5846.
8. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M (2000) Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85: 4081-4086.
9. Nishihara E, Nagayama Y, Mawatari F, Tanaka K, Namba H, Niwa M, Yamashita S (1997) Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 138: 4577-4583.
10. Smit JW, Schroder-van der Elst JP, Karperien M, Que I, Romijn JA, van der Heide D (2001) Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma. Exp Clin Endocrinol Diabetes 109: 52-55.
11. Schmutzler C, Kohrle J (2000) Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10: 393-406.
12. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, Grunwald F, Muller-Gartner HW, Schmutzler C, Kohrle J, Roher HD, Reiners C (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29: 775-782.
13. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J (2001) Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86: 4965-4969.
14. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL (1995) Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195-198.
15. Beer TM, Myrthue A, Eilers KM (2005) Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol 23: 28-32.
16. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD (2001) Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28: 49-55.
17. Beer TM, Myrthue A (2004) Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 3: 373-381.
18. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397.
19. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404.